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IntroductIon
Rheumatoid Arthritis (RA) is a chronic multisystem di -
sease with an estimated occurrence of 1 to 2 percent of
the world population1. RA patients have an increased
risk of cardiovascular (CV) events with high morbidi-
ty and mortality as a result of rapid atherosclerosis2.
Interestingly, RA and atherosclerosis are both chro -
nic inflammatory diseases sharing inflammatory
biomarkers as well as a similar cellular activation pat-
tern. The development of CV disease in RA patients has
been associated with inflammation and autoimmunity.
Considering the previously mentioned incidence of CV
events in patients with RA, the identification of high
risk RA individuals that may benefit from treatment,
should be an important step in order to prevent overt
CV disease. In this regard, in asymptomatic RA patients,
several non-invasive surrogate markers have demon-
strated the presence of subclinical atherosclerosis3,4.
However, information on serological biomarkers of
CVD in patients with RA is limited5.
Endothelial dysfunction itself is a process that in-
volves genetic characteristics, cardiovascular risk fac-
tors, and inflammation6. Endothelin-1 (ET-1)7 which is
mainly secreted by endothelial cells is a potent en-
dogenous vasoconstrictor. It acts through two different
types of receptors: ETA and ETB. ET-1 contributes to
the development of inflammatory processes in the vas-
cular wall, increasing superoxide anion production and
cytokine secretion. It has been found to be associated
with the activation of transcription factors such as nu-
clear factor (NF)- B and also the expression of proin-
flammatory cytokines8. In turn, these transcription fac-
tors and proinflammatory cytokines stimulate ET-1
production9. Bellisai et al.10 report that ET-1 increases
the synthesis of TNF-a in macrophages and monocytes,
which enhances the inflammatory response by stimu-
lating the chemotaxis and phagocytosis of ma -
crophages, monocytes and neutrophils. In different
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AbstrAct 
Objective: The purpose of this study was to evaluate
serum Endothelin-1(ET-1) levels in female Rheumatoid
Arthritis (RA) patients compared with healthy controls,
examine possible associations between ET-1 with dif-
ferent characteristic of the disease and investigate pos-
sible associations between ET-1 with surrogate markers
of cardiovascular disease (CVD). 
Methods: This cross-sectional study was performed in
Vega-Baja Hospital, Orihuela (Spain) from November
2016 to May 2018. Sixty-three women with RA and
sixty-five age and sex healthy controls were included in
this study. Serum ET-1 was analyzed using ELISA. 
Results: Serum levels of ET-1 in RA female patients
were higher than those in healthy controls (p  0.001).
Serum le vels of ET-1 were positively associated with N-
terminal pro-brain natriuretic peptide (NT-proBNP) (r
= 0.27, p < 0.05) and with C-reactive protein (CRP) (r
= 0.36, p < 0.05).  ET-1 levels in women with RA were
higher in smokers. Pre dnisone use was associated with
lower ET-1 levels. No association with carotid intima
media thickness was found.
Conclusions: we observed the presence of higher le -
vels of serum ET-1 in RA women patients compared
with healthy controls.  These increased levels of ET-1
are associated with inflammation and smoking and re-
duced by prednisone intake.  
Keywords: Endothelin-1; Rheumatoid Arthritis; CRP;
NT-proBNP; Prednisone.
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types of cells, increased production of reactive oxygen
species (ROS) occurs via the NF- B, cyclooxygenase
(COX) and nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase-dependent pathways11-13.
The objectives of this study were to analyze ET-1 in
a cohort of women with RA, examine possible associa -
tions between ET-1 with different characteristic of the
disease and investigate possible associations between
ET-1 with surrogate markers of CVD. 
mAterIALs And methods
PAtIent seLectIon
The study was performed in Vega-Baja Hospital, Ori-
huela (Spain) from November 2016 to May 2018. We
prospectively enrolled 63 consecutive women patients
affected by RA and 65 healthy women who served as
controls. All patients included in this study had nor-
mal serum creatinine (Cr) levels, and met the 2010
American College of Rheumatology/European League
Against Rheumatism  (ACR/EULAR) criteria for RA14.
Individuals with prevalent cardiovascular disease were
excluded.
At the clinic visit, participants completed question-
naires about their lifestyle characteristics, medical his-
tory, and current medication used. Informed consent
was obtained for all subjects, and the study was appro -
ved by the Research Ethics Committee of Hospital Uni-
versitario de Elche in Alicante, Spain, date:
22/11/2016, protocol number: pi35/2016 and con-
ducted in accordance with the guidelines in the Dec-
laration of Helsinki.
cArdIovAscuLAr Assesment
Disease severity was scored through disease activity
score of 28 joints and joint damage was evaluated
based on the Steinbrocker radiographic crite ria (I-IV).
Current smokers were defined as those who reported
having smoked ≥1 cigarette per day regularly during
the year preceding the examination. Waist circumfer-
ence, weight, and height were measured; and body
mass index (BMI) was calculated as weight (kg)/height
(m2). Blood pressure (BP) was measured twice in the
left arm of the seated subject with a mercury column
sphygmomanometer. The average of the 2 readings
was used as the examination BP, and hypertension was
defined as self-reported antihypertensive medication
use, or a systolic BP ≥140 mm Hg, or a diastolic BP
≥90 mm Hg. Type 2 diabetes mellitus (T2DM) was de-
fined by self-reported use of insulin, or oral hypo-
glycemic medications, or a fasting glucose level ≥126
mg/dl. Kidney function was assessed using the esti-
mated glomerular filtration rate (eGFR) calculated by
the CKD-Epi study equation15.
The CV risk was assessed using the Modified Sys-
temic Coronary Risk Evaluation (mSCORE). The
mSCORE was calculated using validated risk tables for
both low and high risk populations16.  For this study,
the low risk table was used since Spain has been clas-
sified as a low risk country for CVD. Carotid intima-
media thickness (c-IMT) was measured by perform-
ing carotid ultrasound examination in the common
carotid artery and the detection of focal plaques in the
extracranial carotid tree by manual technique using a
commercially available scanner equipped with 7–12
MHz linear transducer as the patient was lying in the
supine position with the neck rotated to the opposite
side of examination as previously reported17. Carotid
plaques were counted in each territory and defined as
no plaque, unilateral plaque or bilateral plaques17. Val-
ues of cIMT greater than 0.9 mm were considered ab-
normal (cIMT thickening) and plaques were defined if
the cIMT was greater than 1.5 mm18. In our study, an-
kle-arm index was evaluated using a BIDOP model ES-
100V3 vascular screening system (Hadeco, Inc,
Kawasaki, Japan). 
LAborAtory meAsurements
In all the cases, a fasting blood sample was taken in
the morning, and was stored at -70°C until the assays
were performed.
The sera were tested for creatinine, CRP, NT-ProB-
NP and ET-1.  Creatinine was determined by Jaffe
method (Siemens Healthcare Diagnostic Inc. NY,
USA). CRP was measured by turbidimetric im-
munoassay (Siemens Healthcare Diagnostic Inc. NY,
USA).   NT-proBNP was quantified in heparinised plas-
ma using a solid-phase two-site chemiluminescent im-
munometric assay (Biomérieux, France). Serum ET-1
(Elabscience, USA) was measured by ELISA according
to the manufacturer’s recommendations. Anti-citrulli-
nated protein antibodies (ACPAs) were detected using
a second-generation ELISA (ACPAs) kit (ORGENTEC
Diagnostika GmbH. Mainz, Germany) while IgM RF
was determined as part of routine analysis by turbidi-
metric assay (Siemens Healthcare Diagnostic Inc. NY,
USA) according to the manufacturers’ instructions.
Fasting plasma glucose was measured in fresh speci-
mens with a hexokinase reagent kit (Siemens Health-
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cluded in our study as controls; mean age (SD) 52 ± 9
years.  Most of them were also Caucasian (98.3%).
LAborAtory resuLts
Laboratory tests of the patients and healthy controls in-
cluded in the present study are shown in Tables I and II. 
Forty-six (73.0%) and 45 (71.4%) of the 63 wom-
en with RA were positive for rheumatoid factor and 
ACPAs, respectively. As expected, laboratory markers of
inflammation found at the time of the study were high-
er in women with RA than in controls (Table I). In this
regard, the mean CRP in RA patients was 0.6 ± 0.8
mg/dl versus 0.2 ± 0.1 mg/dl in controls (p <0.001).
Likewise, the mean ESR in the group of RA patients
was 23.9 ± 15.8 mm/1st hour versus 11.3 ± 10.2 mm/1st
hour in controls (p <0.001) (Table I). Patients with RA
had lower uric acid levels than controls (3.9 ± 1.3 ver-
sus 4.6 ± 1.3 mg/dl; p= 0.002). However, NT-proBNP
levels were higher in patients with RA (79.8 ± 54.8 ver-
sus 59.7± 38.4 pg/ml in controls; p= 0.01).
Interestingly, the serum ET-1 concentrations were
significantly higher in the RA patients than those in the
control group: [28.9 (0-50) vs. 21.7 (0-50), pg/ml; p
 0.001] (Figure 1). 
cArdIovAscuLAr dIseAse rIsk fActors
As shown in Table I, patients had a mean BMI of
26.6±5.6 kg/m2, waist circumference of 103.8± 13.2
cm, ankle-arm index of 1.1±0.1, cIMT of 0.7±0.1 mm,
mSCORE 2.0 ± 2.3. Fourteen (22%) of them had a
smoking history.
Healthy controls had a mean BMI of 25.9 ± 4.3
kg/m2, waist circumference of 83.1 ± 13.4 cm, ankle-
arm index of 1.2 ± 0.2, cIMT of 0.6 ± 0.2 mm,
mSCORE 1.8 ± 2.5. Fourteen (21.5%) of them had a
smoking history.
reLAtIonshIP between et-1 LeveLs And 
cArdIovAscuLAr rIsk fActors or dIseAse
feAtures In PAtIents wIth rheumAtoId
ArthrItIs
Table III shows the correlation coefficients between ET-
1 and other markers in patients with RA.  Levels of ET-
1 were significantly correlated with smoking (p=
0.020). ET-1 levels also showed a statistically significant
positive correlation with CRP (r = 0.36, p= 0.004) and
with NT-proBNP (r = 0.27, p= 0.036). In contrast, an
inverse correlation between prednisone intake and ET-
1 levels (p= 0.034). However, there was no correlation
of ET-1 levels with age, BMI, ankle-arm index, cIMT,
care Diagnostic Inc. NY, USA). Total cholesterol and
triglyceride levels were determined by fully enzymatic
techniques. High-density lipoprotein (HDL) was de-
termined after precipitation of apolipoprotein B
(apoB)–containing lipoproteins with magnesium sul-
fate and dextran sulfate. Low-density lipoprotein (LDL)
was calculated using the Friedewald formula. All oth-
er routine serum biochemical parameters were mea-
sured at the Department of Clinical Chemistry, Vega-
Baja Hospital.
stAtIstIcAL AnALysIs 
Data were analyzed by statistical software SPSS 18
(Chicago, IL, USA) and with the program R version
Rx64.3.5.0 (Vienna, Austria), using independent sam-
ples t-test, Mann-Whitney U test, and Chi-square test
when appropriate. Spearman’s coefficient and Pearson’s
correlation were calculated as suitable to determine the
correlation between the bio-chemical parameters. 
P-values of less than 0.05 were considered statistically
significant. The quantitative data were shown as mean
± standard deviation (SD) and median (Q1–Q3) as
suita ble. To test if we can admit that the distribution is
normal we use the Shapiro-Wilk test. Linear regression
was used to examine the cross-sectional associations of
plasma ET-1 concentrations with CRP and NT-proBNP.
resuLts
chArActerIstIcs of the study subjects
The main features of the 63 women with RA and 65
controls included in this study are shown in Table I.
The mean age (SD) of the patients was 53 ± 8 years.
The majority were Caucasian (90.5%). The mean disea -
se duration was 8.5 ± 5.8 years. The mean disease ac-
tivity score in 28 joints (DAS28) according to the ery-
throcyte sedimentation rate (ESR) indicated low disea se
activity 3.0 ± 1.3. The mean health assessment ques-
tionnaire (HAQ) was 0.75 ± 0.67. The mean Stein-
brocker s stage was 2.75 ± 1.17 and the mean Stein-
brocker s class 1.87 ± 0.69. At the time of the study 32
(50.7%) patients were receiving biologic agents (9 eta -
nercept, 9 certolizumab pegol, 7 tocilizumab, 6 adali-
mumab and 1 rituximab). Most patients (73%) had re-
ceived or were undergoing methotrexate therapy (mean
weekly dose 11.5 ± 4.8 mg in patients on methotrexa -
te) and 16 patients took prednisone with a median dai-
ly dose of 6.5 ± 3.5 mg. 
In addition, a total of 65 healthy women were in-
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tAbLe II. serum et-1 And study PArAmeters of rA PAtIents And heALthy controLs
RA HC
mean ± SD mean ± SD p-value
ET-1, pg/ml 28.9 ± 12.6 21.7 ± 11.7 <0.001
Cholesterol, mg/dl 212.7 ± 41 211.8 ± 37.3 0.89
LDL-C, mg/dl 120.1 ± 29.2 129.7 ± 30.7 0.06
HDL-C, mg/dl 69.9 ± 19.4 63.3 ± 13.1 0.02 
Triglycerides, mg/dl 112.9 ± 55.6 107.7 ± 53.9 0.59
Uric acid, mg/dl 3.9 ± 1.3 4.6 ± 1.3 0.002
NT-proBNP, pg/ml 79.8 ± 54.8 59.7 ±  38.4 0.01
Fe, mg/dl 77.7 ± 28.9 85.6 ± 32.3 0.14
SD: standard deviation, RA: rheumatoid arthritis, HC: healthy control, ET-1: endothelin 1, LDL: low density lipoprotein, HDL: high density
lipoprotein, Fe: iron, NT-proBNP: prohormone brain natriuretic peptide.
tAbLe I. chArActerIstIcs of women wIth rheumAtoId ArthrItIs And heALthy controLs
RA HC
mean ± SD mean ± SD p-value
Age, years 53.1 ± 8.3 52.7 ± 9.7 0.80
Height, cm 160.8 ± 6.2 169.9 ± 7.1 <0.001
Body weight, kg 68.7 ± 14.5 67.2 ± 12 0.52
Body mass index, kg/m2 26.5 ± 5.6 25.9 ± 4.3 0.49
Waist circumference 103.8 ± 13.1 83.1 ± 13.4 <0.001
Ankle-arm index 1.1 ± 0.1 1.2 ± 0.2 <0.001
cIMT  mm 0.7 ± 0.1 0.6 ± 0.2 <0.001
mSCORE 2 ± 2.3 1.8 ± 2.5 0.63
Duration of RA, years 8.5 ± 5.8 – –
DAS28-ESR 3 ± 1.3 – –
HAQ 0.75 ± 0.67 – –
Steinbrocker’s stage 2.75 ± 1.17 – –
Steinbrocker’s class 1.87 ± 0.69 – – 
Smoking, n (%) 14 (22.2) 14 (21.5) 0.47
Hypertension, n (%) 10 (15.8) 11 (16.9) 0.87
Diabetes mellitus, n (%) 3 (4.7) 2 (3) 0.62
Dyslipidemia, n (%) 13 (20.6) 14 (21.5) 0.57
Prednisone, mg/day 6.5 ± 3.5 – –
Methotrexate, mg/week 11.5 ± 4.8 – –
Biologic agent use, n (%) 32 (50.7) – –
RF positive, n (%) 46 (73) – –
ACPAs positive, n (%) 45 (71.4) – –
CRP, mg/dl 0.6 ± 0.8 0.2 ± 0.1 <0.001
ESR, mm/h 23.9 ± 15.8 11.3 ± 10.2 <0.001
Serum creatinine, mg/dl 0.58 ± 0.11 0.7 ± 0.2 <0.001 
eGFR, ml/min 108.7 ± 28.7 99 ± 13.2 0.01
SD: standard deviation, RA: rheumatoid arthritis, HC: healthy control, DAS: disease activity score, ESR: erythrocyte sedimentation rate, 
CRP: C-reactive protein, eGFR:  estimated glomerular filtration rate, RF: Rheumatoid Factor, ACPAs: Anti-citrullinated protein antibodies,
HAQ: Health Assessment Questionnaire, cIMT: Carotid intima-media thickness, mSCORE: Modified Systemic Coronary Risk Evaluation.
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disease duration, disease activity or ACPA or RF status
(Table III).
In the linear regression model, higher log10 ET-1
concentrations were associated with higher CRP 
[ = 0.024 95% CI (0.041, 0.008); p= 0.004] and 
NT-proBNP [ = 1.173 95% CI (2.246, 0.098); p=0.032].
dIscussIon
RA is an inflammatory, systemic, autoimmune, chron-
ic disease of unknown cause, characterized by physi-
cal disability, progressive destruction of the joints and
increased mortality, mainly due to CVD19,20. 
ET-1 might play an important role in inflammatory
processes and vasculopathy in connective tissue dis-
eases (CTD) as a potent physiological vasoconstrictor,
released after activation and/or damage of endothelial
cells21. In various autoimmune diseases such as sys-
temic lupus erythematosus (SLE)22, systemic sclerosis
(SSc)23 or RA24, increased plasma ET-1 levels have been
found. Moreover, elevated ET-1 serum levels have been
implicated in the pathophysiology of both vascular and
fibrotic manifestations in SSc23. Increasing evidence
suggests a potential central role of endothelial dys-
function in RA pathogenesis25-27, specifically in patients
with high inflammatory activity28. Furthermore, some
other studies suggest that chronic inflammation in the
course of RA leads to endothelial function impairment,
regardless of the disease activity29. Either by the prolif-
eration of new blood vessels or by over expression of
inflammatory mediators, the endothelial cells play a
key role in the systemic disease process and further in-
ternal organ damage26,30. 
In our study, we found significantly elevated plasma
ET-1 levels in women with RA compared with healthy
controls. Clinical studies also reported elevated plasma
levels of ET-1 in patients with RA31-33. 
ET-1 can stimulate the production of pro-inflam-
matory cytokines such as interleukin-6, and CRP is in-
duced by IL-6 during inflammation. In keeping with
that, we observed a statistically significant positive cor-
relation between ET-1 levels and CRP levels.
Different studies have evaluated the relationship be-
tween ET-1 and CRP. Plasma ET-1 levels are found ele-
vated and correlated with CRP in patients with inflam-
matory pathologies such as acute ischemic stroke34,
exacerbations of chronic obstructive pulmonary di -
sease35, and acute myocardial infarction treated with
direct coronary angioplasty36. 
fIGure 1. Median serum concentration of Endothelin-1 (ET-1) in Rheumatoid Arthritis patients and healthy controls. 2 tailed Mann
Whitney U test for unpaired sample. HC: healthy controls; RA: Rheumatoid arthritis.
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monary epithelial cell line under stimulated or basal
conditions. In line with these findings, we disclosed a
negative correlation between ET-1 levels and the use of
prednisone. With respect to this, patients from our se-
ries who were on treatment with prednisone had low-
er levels of ET-1. 
A close relationship exists between the natriuretic
peptides of the cardiovascular system and ET-1. Dif-
ferent studies have shown ET-1 to be a potent stimula-
tor of the synthesis and release of these peptides in car-
diac tissues38,39. It has also been suggested that part of
the vasodilatory action of these natriuretic peptides
might be due to a reduction in the basal production of
ET-140,41. The hypothesis has been advanced that con-
tributing to the regulation of vascular tone, a feedback
mechanism exists between them42,43. Interestingly, we
disclosed a significant positive correlation between 
ET-1 levels and NT-proBNP levels in our patients with
RA, which was independent of age. 
 liwi ska-Mosso  et al.44 found that tobacco smoking
has a direct effect on the endothelium, leading to an
increased level of ET-1. Bossard et al.45 observed a signi -
ficant correlation of ET-1 with smoking. In agreement
with these observations, we also found a significant
asso ciation between ET-1 levels and smoking status in
patients with RA.
In our study we could not confirm a correlation be-
tween disease activity, disease duration or RF/ACPA
seropositivity with ET-1 levels. It was also the case for
cIMT or traditional CV risk factors.
There are several limitations in our study that should
be considered. First, this study was a cross-sectional
analysis that reflected the status of a population in a
particular period. The cross-sectional design of this
study does not allow drawing causal inferences. This
study focused only on RA women; therefore, the find-
ings of this study cannot be generalized to men with
RA. However, it has a number of strengths derived from
the monocentric design of the study with the inclusion
of consecutive RA patients homogeneously evaluated
and the careful analysis of data performed by a dedi-
cated physician.
concLusIons
We observed the presence of higher levels of serum ET-1
in RA women compared with healthy controls. These in-
creased levels of ET-1 are associated with inflammation
and smoking and reduced by prednisone intake.
tAbLe III. correLAtIons between et-1 And






Body weight -0.07 0.604
Body mass index -0.05 0.688
Waist circumference -0.05 0.697
Smoking 0.29 0.020
Hypertension -0.13 0.306
Ankle-arm index -0.22 0.089
cIMT -0.12 0.359
Carotid plaques -0.10 0.438
mSCORE 0.02 0.862
Disease duration of 
rheumatoid arthritis -0.12 0.339
DAS28-ESR -0.14 0.282
HAQ -0.06 0.629
Methotrexate dose 0.18 0.343  
Prednisone dose -0.47 0.034
Biological agent use 0.04 0.972
RF 0.00 0.987
ACPAs 0.10 0.435
C-reactive protein 0.36 0.004
Erythrocyte 
sedimentation rate 0.19 0.149 
Fibrinogen 0.16 0.213
Serum creatinine 0.00 0.998
Serum urea 0.00 0.976
eGFR 0.07 0.064  
Cholesterol, mg/dl 0.09 0.474  
LDL-C, mg/dl 0.16 0.216 
HDL-C, mg/dl -0.04 0.751   
Triglycerides, mg/dl 0.00 0.976   
Uric acid, mg/dl -0.13 0.302   
NT-proBNP, pg/ml 0.27 0.036  
Fe, mg/dl 0.21 0.102   
cIMT: Carotid intimal medial thickness, m-SCORE: modified
systematic coronary risk evaluation, DAS: disease activity score,
HAQ: Health Assessment Questionnaire , RF: rheumatoid factor,
ACPAs: Anti-citrullinated protein antibodies, eGFR: estimated
glomerular filtration rate, LDL: low density lipoprotein, HDL: high
density lipoprotein; Fe: iron
Calderon et al.37 observed that dexamethasone and
triamcinolone acetonide down-regulate the production
and synthesis of ET-1 by a transformed human pul-
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